Ahmed Hamdy MD - 17 Mar 2026 Form 4 Insider Report for CURIS INC (CRIS)

Role
CMO
Signature
/s/ Diantha Duvall, Attorney-in-fact
Issuer symbol
CRIS
Transactions as of
17 Mar 2026
Net transactions value
$0
Form type
4
Filing time
18 Mar 2026, 16:21:54 UTC
Previous filing
05 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hamdy Ahmed MD CMO 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON /s/ Diantha Duvall, Attorney-in-fact 18 Mar 2026 0001458506

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRIS Series B Convertible Preferred Stock Award +50 50 17 Mar 2026 Common Stock 66,667 Direct F1, F2
transaction CRIS Series A Warrant (right to buy) Award +66,667 66,667 17 Mar 2026 Common Stock 66,667 $0.7500 Direct F2, F3
transaction CRIS Series B Warrant (right to buy) Award +66,667 66,667 17 Mar 2026 Common Stock 66,667 $0.7500 Direct F2, F4
transaction CRIS Series C Warrant (right to buy) Award +66,667 66,667 17 Mar 2026 Common Stock 66,667 $0.7500 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).
F2 Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.
F3 Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026.
F4 The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.
F5 The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026.